



## COVID-19 Vaccines: The Way Back to Normal Life Is Now Marked

Guest Editors:

### **Prof. Dr. Matteo Bassetti**

1. Department of Health Sciences, University of Genoa, 16126 Genoa, Italy  
2. Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy

### **Dr. Antonio Vena**

1. Department of Health Sciences, University of Genoa, 16126 Genoa, Italy  
2. Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy

Deadline for manuscript submissions:

**closed (22 July 2022)**

### **Message from the Guest Editors**

The SARS-CoV-2 virus has dramatically changed our lives, representing a serious public health problem with substantial morbidity and mortality and resulting in considerable economic damage worldwide. Despite nationwide lockdowns trying to control the widespread diffusion of the virus, more than 2.5 million infected individuals have died from COVID-19 over the last year.

There are very few therapeutic options to date, and COVID-19 vaccine development has been accelerated in hope of rapidly containing the pandemic and returning to 'normal life'. Several vaccines have already been commercialized and are distributed in nationwide mass immunization campaigns. The aim of this Special Issue is to summarize general knowledge of COVID-19 vaccine responses in general and special populations (e.g., pediatric population, adolescents and pregnant women) and to discuss current knowledge, current recommendations and controversies regarding COVID-19 vaccination





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)